Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.10.2023 | Case report

Brexucabtagene-autoleucel

Flare of graft-versus host disease and lack of efficacy: 2 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wang Y, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology 41: 2594-2606, No. 14, 10 May 2023. Available from: URL: https://ascopubs.org/loi/jco Wang Y, et al. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology 41: 2594-2606, No. 14, 10 May 2023. Available from: URL: https://​ascopubs.​org/​loi/​jco
Metadaten
Titel
Brexucabtagene-autoleucel
Flare of graft-versus host disease and lack of efficacy: 2 case reports
Publikationsdatum
01.10.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-47153-7

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Cantharidin

Case report

Tepotinib

Case report

Heparin